Table 4.
Secondary endpoints: serum, urine, and radiographic correlative studies
| Secondary endpoints | Pre-treatment Mean (SD) | Post-treatment Mean (SD) | p Value (t test) |
|---|---|---|---|
| Serum lipid levels | |||
| Total cholesterol (mg/dl) | 202 (45.7) | 194 (39.6) | 0.51 |
| LDL (mg/dl) | 121 (34.3) | 115 (32.1) | 0.53 |
| Serum markers | |||
| CRP (pg/mL | 1.22 (1.77) | 0.973 (1.22) | 0.61 |
| IGF-1 (ng/mL) | 17.4 (4.38) | 15.3 (4.96) | 0.16 |
| IGFBP-3 (ng/mL) | 19.9 (5.45) | 20.6 (5.62) | 0.69 |
| IGF-1/IGFBP-3 ratio | 0.915 (0.313) | 0.778 (0.274) | 0.15 |
| Urine markers | |||
| Lipid peroxidation (pg/mg) | 8,422 (5451) | 8,241 (6537) | 0.91 |
| Oxidative DNA damage (8-oxo-dG) (ng/mL) | 104 (84.3) | 138 (97.3) | 0.18 |
| Mammographic density, BI-RADSa | 2.77 (1.11) | 2.67 (1.08) | 0.79 |
| Genotype (%, 95 % CI) | |
|---|---|
| HMGCR genotypeb | A/A (50.0 %, 32.1–67.9 %)b |
| A/T (38.5 %, 22.4–57.5 %) | |
| T/T (11.5 %, 3.2–29.8 %) |
Lipid levels were available for 25 participants, serum markers for 20 participants, and mammographic density for 18 participants. Lipid peroxidation, oxidative DNA damage, and HMGCR genotypes were available for all 26 participants
a
BI-RADS composition system for mammographic density assessment: 1 (predominantly fatty), 2 (scattered fibroglandular densities), 3 (heterogeneously dense), and 4 (extremely dense) [27]
b
No correlation was observed with HMGCR genotype and changes in lipid levels